Madurai News

Vascular Dementia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Vascular Dementia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

October 03
18:46 2022
Vascular Dementia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Vascular Dementia Market
DelveInsight’s ‘Vascular Dementia -Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Vascular Dementia historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

DelveInsight’s Vascular Dementia -Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of Vascular Dementia historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Vascular Dementia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Vascular Dementia market size from 2019 to 2032. The Report also covers current treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Vascular Dementia   Market Report:

  • In 2021, the EU-5 accounted for 893,124 diagnosed  prevalent cases which will increase by 2032
  • In the US, out of all age groups, the highest diagnosed cases were contributed by the age group 81–90 years,  followed by 71–80 years. While the least cases were reported in the 60–70 years age group, in 2021.
  • In 2021, Japan had 791,660 diagnosed cases ranking second-highest among 7MM. These cases are expected to increase by 2032 during the forecasted period (2022–2032.

 

Key benefits of the Vascular Dementia Market report:

 

  • The report covers the descriptive overview of Vascular Dementia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Vascular Dementia epidemiology and treatment.
  • Additionally, an all-inclusive account of the current and emerging therapies for Vascular Dementia is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Vascular Dementia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Vascular Dementia market.

 

Got queries? Click here to know more about the Vascular Dementia Market Landscape 

Vascular Dementia Overview

The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving, or language. In vascular dementia, these symptoms occur when the brain is damaged because of problems with blood supply to the brain. Vascular dementia is an etiological category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypoperfusion affecting brain regions important for memory, cognition, and behavior. Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and number of vascular changes.

 

A growing number of experts prefer the term “vascular cognitive impairment” (VCI) to “vascular dementia” because they feel it better expresses the concept that vascular thinking changes can range from mild to severe. According to the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline, can be classified into four major subtypes: Post-stroke dementia (PSD) defined as dementia manifesting within 6 months after a stroke; Subcortical ischemic vascular dementia; Multi-infarct (cortical) dementia; and mixed dementia.

 

Caused by different conditions that interrupt the flow of blood and oxygen supply to the brain and damage blood vessels in the brain.

 

Vascular Dementia Epidemiological Insights:

  • World Health Organization (n.d.) described dementia as a syndrome in which there is deterioration in cognitive function beyond what might be expected from the usual consequences of biological aging. Vascular dementia is the second most common type of dementia, in which a decline in thinking skills is caused by conditions that block or reduce blood flow to various regions of the brain, depriving them of oxygen and nutrients.
  • As per the assessment of DelveInsight, the total prevalent cases of dementia in the 7MM were found to be  21,591,565 in 2021, which are expected to increase during the study period 2019-2032.
  • The diagnosed prevalent cases of dementia in the 7MM were found to be 11,344,408 in 2021, which are expected to increase for the study period of 2019-2032.
  • As per DelveInsight’s estimates, 7MM accounts for 2,795,390 diagnosed prevalent cases of in 2021,  which are expected to increase during the study period 2019-2032.
  • Among 7MM, the United States had the highest diagnosed cases of with 1,110,606 cases in 2021, which was equivalent to 40% of total diagnosed prevalent cases in 7MM.

Vascular Dementia Epidemiological Segmentation

  • Vascular Dementia prevelant cases 
  • Vascular Dementia diagnosed cases
  • Vascular Dementia Age-specific cases 

Vascular Dementia Market Outlook 

Vascular dementia is a common condition with no effective approved pharmacological treatments available. Vascular dementia arises from ischemic insults such as hemorrhage and hypoperfusion that trigger neurodegeneration by depriving nerve cells of oxygen and glucose.

 

has multifactorial etiopathology, diverse clinical manifestations, and multiple clinical subtypes. Moreover, the diagnostic criteria are not consistent worldwide.

 

Although patients with constitute the second-largest dementia population, treatment data are lacking. There are no effective pharmacological compounds approved for the treatment of vascular dementia in any jurisdiction worldwide. Controlling medical conditions that impact cardiovascular health is recommended to prevent further decline. For example, medications can be prescribed to control blood pressure, cholesterol, heart disease, and diabetes. Aspirin or other drugs may be prescribed to prevent clots from forming in blood vessels

According to DelveInsight, the Vascular Dementia treatment paradigm in the 7MM is expected to change during the forecasted period 2022–2032.

 

Learn more by requesting for sample @Vascular Dementia Market Landscape

Vascular Dementia Key Companies  

  • Chasire  Biotechnology  Corp
  • Cyclerion Therapeutics
  • And many others

Vascular Dementia Therapies 

  • BAC
  • CY64
  • And many others

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Vascular Dementia   Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Vascular Dementia   Market   Emerging Therapies
  • Vascular Dementia   Market  Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  • Vascular Dementia   Market  Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Click here to read more about Vascular Dementia Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/